Efficacy and safety of peginterferon alpha-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern Europe
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F11%3A00052186" target="_blank" >RIV/00216224:14110/11:00052186 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1097/MEG.0b013e3283458407" target="_blank" >http://dx.doi.org/10.1097/MEG.0b013e3283458407</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1097/MEG.0b013e3283458407" target="_blank" >10.1097/MEG.0b013e3283458407</a>
Alternative languages
Result language
angličtina
Original language name
Efficacy and safety of peginterferon alpha-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern Europe
Original language description
Methods: HCV genotype 1 patients previously treated with conventional interferon with or without ribavirin were assigned to 48 weeks of treatment with peginterferon alfa-2a (40KD) 180 mcg/week plus ribavirin (recommended dose 1000/1200 mg/day) in this open-label trial conducted in Central and Eastern Europe. The primary efficacy endpoint was sustained virological response (SVR, HCV RNA <50 IU/mL) after 24 weeks of untreated follow-up. Early virological response (EVR) was defined as undetectable HCV RNA or minimally 2-log drop at week 12. Results: 154/203 (76%) treatment-experienced genotype 1 patients completed treatment. Overall, 113 patients (56%) achieved an EVR, 107 (53%) had an end-of-treatment response and 63 patients (31%) achieved an SVR (including 38% [40/105] of those with prior breakthrough or relapse and 24% [21/88] of those with prior non-response).
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FN - Epidemiology, infection diseases and clinical immunology
OECD FORD branch
—
Result continuities
Project
—
Continuities
S - Specificky vyzkum na vysokych skolach
Others
Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
European Journal of Gastroenterology & Hepatology
ISSN
0954-691X
e-ISSN
—
Volume of the periodical
23
Issue of the periodical within the volume
5
Country of publishing house
GB - UNITED KINGDOM
Number of pages
7
Pages from-to
375-381
UT code for WoS article
000289506800002
EID of the result in the Scopus database
—